Green light to the acquisition of the Labexa Group by the Cerba Group, subject to conditions

Published on December 23, 2021

The transaction does not affect competition in the markets for the supply to suppliers. Nor does it raise any competition issues in the routine chemical pathology markets in most of the local areas studied. However, the *Autorité* considered that there was a serious risk of harm to competition in the market for routine chemical pathology tests in the Hautes-Pyrénées *département*.

To maintain competitive intensity in this *département*, the new entity has committed to divest the medical analysis site currently owned by Labexa and located in Maubourguet (65700). The effect of this divestiture is to remove the overlapping activities resulting from the transaction in this area.

In view of the commitments made by Cerba, the *Autorité* has cleared the present transaction.

PRESS RELEASE

of 23 December 2021

See the press release